Prima BioMed’s CVac Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO

March 28, 2014 Prima BioMed LtdĀ announced today that the American Society of Clinical Oncology has accepted the abstract entitled, “Progression-free survival in ovarian cancer patients in second remission is improved with mucin-1 autologous dendritic cell therapy” for oral presentation at the Gynecologic Cancer Session at the 2014 ASCO Annual Meeting to be held May 30 – June 3, 2014 in …